EDSA (Edesa Biotech) Gross Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Edesa Biotech's Gross Profit for the three months ended in Dec. 2024 was $0.00 Mil. Edesa Biotech's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Edesa Biotech's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Edesa Biotech's Gross Margin % or its related term are showing as below:

During the past 13 years, the highest Gross Margin % of Edesa Biotech was 94.53%. The lowest was -134.21%. And the median was 0.26%.

EDSA's Gross Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: 60.3
* Ranked among companies with meaningful Gross Margin % only.

Edesa Biotech had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Edesa Biotech was 0.00% per year.

Edesa Biotech Gross Margin % Historical Data

The historical data trend for Edesa Biotech's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech Gross Margin % Chart

Edesa Biotech Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Gross Margin %

Get a 7-Day Free Trial

94.53

Edesa Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Edesa Biotech's Gross Margin %

For the Biotechnology subindustry, Edesa Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edesa Biotech's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's Gross Margin % falls into.

Edesa Biotech Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Edesa Biotech's Gross Margin for the fiscal year that ended in Sep. 2024 is calculated as

Gross Margin % (A: Sep. 2024 )	=	Gross Profit (A: Sep. 2024 )	/	Revenue (A: Sep. 2024 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

Edesa Biotech's Gross Margin for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )	=	Gross Profit (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0 - 0)	/	0
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Edesa Biotech (NAS:EDSA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Edesa Biotech had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Edesa Biotech Gross Margin % Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Edesa Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Spy Court, Markham, ON, CAN, L3R 5H6

Website

https://www.edesabiotech.com

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Executives

Pardeep Nijhawan	director, 10 percent owner, officer: Chief Executive Officer	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Stephen Lemieux	officer: Chief Financial Officer	100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter	director, 10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks	officer: President	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes	director, officer: President, CEO, & Director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson	director	3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp	10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse	director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041